Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Data-Driven Patterns in Protective Effects of Ibuprofen and Ketorolac on Hospitalized Covid-19 Patients

View ORCID ProfileBenjamin J. Lengerich, Rich Caruana, Yin Aphinayanaphongs
doi: https://doi.org/10.1101/2021.06.15.21258991
Benjamin J. Lengerich
1Massachusetts Institute of Technology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin J. Lengerich
Rich Caruana
2Microsoft Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin Aphinayanaphongs
3NYU Langone Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yin.a@nyulangone.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on patients with Covid-19 has been unclear. A major reason for this uncertainty is the confounding between treatments, patient comorbidities, and illness severity. Here, we perform an observational analysis of over 3000 patients hospitalized for Covid-19 in a New York hospital system to identify the relationship between in-patient treatment with Ibuprofen or Ketorolac and mortality. Our analysis finds evidence consitent with a protective effect for Ibuprofen and Ketorolac, with evidence stronger for a protective effect of Ketorolac than for a protective effect of Ibuprofen.

The impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on patients with Covid-19 has been unclear. Initial guidance was to avoid prescription of NSAIDs to Covid-19 patients [1]. However, more recent meta-analyses have suggested that there is no compelling evidence of a harmful effect of ibuprofen on Covid-19 patients [2], [3], [4]. It is difficult to identify the effect of NSAIDs due to confounding; beyond association with long-term comorbidities, NSAID usage in Covid-19 patients may also be caused by more severe cases of Covid-19 which could manifest with inflammatory symptoms [5]. However, other analysis has found no association between ibuprofen and clinical outcomes, even without deconfounding [6].

Moreover, a few observational analyses have indicated that a protective effect from outpatient NSAIDs [7] or ibuprofen 1 appears after correcting for underlying patient risk factors. Finally, there is some evidence of protective effects of NSAIDs on patients with respiratory illnesses [8], although similar clinical trials have not been completed for Covid-19.

In this setting, we seek to use machine learning tools to estimate patient risk at time of admission from patient lab values and then estimate the additive effect of Ibuprofen and Ketorolac. Our outcome is in-hospital mortality. We consider only treatments within 24 hours of hospital admission; this captures a total of 97 patients who were treated with either Ibuprofen or Ketorolac. Our control condition is not receiving either NSAID in the first 24 hours. Our analysis includes deidentified records from 3108 patients hospitalized for Covid-19. This cohort includes patients hospitalized from March to August 2020 with an average mortality rate of 18.1%. In this dataset, mortality rate peaked over 25% and decreased to less than 5% for patients admitted in August 2020.

Treatment assignment is not random and has changed over time with more glucocorticoid prescriptions at later dates [9]. To correct for this and other confounding, we use a two-stage machine learning procedure to estimate the adjusted risk difference (ARD) and adjusted risk ratio (ARR) [10, 11], which can be interpreted as an odds ratio after correcting for patient mortality risk at admission. Our two-stage procedure works as follows: first we take half of the control patients and train a generalized additive model (GAM) [12, 13] to predict mortality from patient features at admission. Because medications can affect patient lab values, we use only initial lab tests which are taken before in-patient medications are administered. In the treated patients (held out from model estimation), we compute the excess risk after accounting for the model predictions of patient risk. To compute standard error, we bootstrap the training sample. The baseline mortality risk model achieves AUC 0.91 on held-out patients. See S3 for details of model construction.

Results of this analysis are shown in Table 1. The observed mortality rate of patients treated with Ibuprofen or Ketorolac is lower than would be expected based on patient risk factors (comorbidities, demographics, and lab tests) at admission. For Ketorolac, the evidence is sufficient to reject a null hypothesis of no effect at p=0.05.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1: Observed and expected mortality rates for patients treated with Ibuprofen or Ketorolac.

These results add to the growing body of evidence that NSAIDs, and in particular Ibuprofen or Ketorolac, may not have detrimental effects on patients hospitalized with Covid-19. While these medications were correlated with a younger subset of the hospitalized patients (Figure. S3) and later treatment dates (Figure. S2), the protective effects remain after correcting for confounding. This suggests that further study should be performed to understand any potential benefits of Ibuprofen and Ketorolac on patients hospitalized with Covid-19. Our study comes with all caveats of observational analyses and we suggest randomized control trials to study treatment protocols.

Data Availability

The data include anonymized medical records, which are not publicly available.

Footnotes

  • ↵1 https://ehrnprd.blob.core.windows.net/wordpress/pdfs/Ibuprofen-and-COVID-19-Severity.pdf

References

  1. [1].↵
    Michael Day. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, 2020.
  2. [2].↵
    Nicholas Moore, Bruce Carleton, Patrick Blin, Pauline Bosco-Levy, and Cecile Droz. Does ibuprofen worsen covid-19ã, 2020.
  3. [3].↵
    Lucinda Smart et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (covid-19), ace2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology, pages 1–12, 2020.
  4. [4].↵
    Paulo Martins-Filho, Edmundo do Nascimento-Júnior, and Victor Santos. No current evidence supporting risk of using ibuprofen in patients with covid-19. International journal of clinical practice, 74(10):e13576, 2020.
    OpenUrl
  5. [5].↵
    Mohit Sodhi and Mahyar Etminan. Safety of ibuprofen in patients with covid-19: causal or confoundedã Chest, 158(1):55, 2020.
    OpenUrl
  6. [6].↵
    Ehud Rinott, Eran Kozer, Yonatan Shapira, Adina Bar-Haim, and Ilan Youngster. Ibuprofen use and clinical outcomes in covid-19 patients. Clinical Microbiology and Infection, 26(9):1259–e5, 2020.
    OpenUrl
  7. [7].↵
    Bettina Experton et al. A predictive model for severe covid-19 in the medicare population.
  8. [8].↵
    Mahmoud Yousefifard, Alireza Zali, Afshin Zarghi, Arian Madani Neishaboori, Mostafa Hosseini, and Saeed Safari. Non-steroidal anti-inflammatory drugs in management of covid-19; a systematic review on current evidence. International Journal of Clinical Practice, 74(9):e13557, 2020.
    OpenUrlPubMed
  9. [9].↵
    LI Horwitz, SA Jones, RJ Cerfolio, F Francois, J Greco, B Rudy, and CM Petrilli. Trends in covid-19 risk-adjusted mortality rates. Journal of Hospital Medicine, 2020.
  10. [10].↵
    Sander Greenland and Paul Holland. Estimating standardized risk differences from odds ratios. Biometrics, pages 319–322, 1991.
  11. [11].↵
    Edward C Norton, Morgen M Miller, and Lawrence C Kleinman. Computing adjusted risk ratios and risk differences in stata. The Stata Journal, 13(3):492–509, 2013.
    OpenUrl
  12. [12].↵
    Trevor J Hastie and Robert J Tibshirani. Generalized additive models, volume 43. CRC press, 1990.
  13. [13].↵
    Rich Caruana, Yin Lou, Johannes Gehrke, Paul Koch, Marc Sturm, and Noemie Elhadad. Intelligible models for healthcare: Predicting pneumonia risk and hospital 30-day readmission. In Proceedings of the 21th ACM SIGKDD international conference on knowledge discovery and data mining, pages 1721–1730, 2015.
Back to top
PreviousNext
Posted June 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Data-Driven Patterns in Protective Effects of Ibuprofen and Ketorolac on Hospitalized Covid-19 Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Data-Driven Patterns in Protective Effects of Ibuprofen and Ketorolac on Hospitalized Covid-19 Patients
Benjamin J. Lengerich, Rich Caruana, Yin Aphinayanaphongs
medRxiv 2021.06.15.21258991; doi: https://doi.org/10.1101/2021.06.15.21258991
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Data-Driven Patterns in Protective Effects of Ibuprofen and Ketorolac on Hospitalized Covid-19 Patients
Benjamin J. Lengerich, Rich Caruana, Yin Aphinayanaphongs
medRxiv 2021.06.15.21258991; doi: https://doi.org/10.1101/2021.06.15.21258991

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (685)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (323)
  • Neurology (2786)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)